血行動態モニタリングシステムの世界市場：装置、消耗品、侵襲型、最小侵襲型、非侵襲型...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.3 MARKET SCOPE 19
1.3.1 MARKETS COVERED 19
1.3.2 YEARS CONSIDERED FOR THE STUDY 20
1.4 CURRENCY & PRICING 20
1.5 LIMITATIONS 20
1.6 STAKEHOLDERS 20

2 RESEARCH METHODOLOGY 21
2.1 RESEARCH DATA 21
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 22
2.2.1 SECONDARY RESEARCH 22
2.2.1.1 Key data from secondary sources 22
2.2.2 PRIMARY RESEARCH 23
2.2.2.1 Key Industry Insights 24
2.2.2.2 Break Down of Primary Interviews: by Company Type, Designation, and Region 25
2.2.2.3 Key data from primary sources 25
2.2.2.4 Key Insights from primary sources 26
2.3 MARKET SIZE ESTIMATION 26
2.3.1 MARKET FORECAST METHODOLOGY 29
2.3.2 MARKET DATA VALIDATION AND TRIANGULATION 29
2.4 ASSUMPTIONS 30

3 EXECUTIVE SUMMARY 31
3.1 INTRODUCTION 31
3.2 CURRENT SCENARIO 32
3.3 FUTURE OUTLOOK 33
3.4 CONCLUSION 34

4 PREMIUM INSIGHTS 35
4.1 GLOBAL HEMODYNAMIC MONITORING SYSTEMS MARKET 35
4.2 HEMODYNAMIC MONITORING SYSTEMS MARKET, BY REGION AND TYPE 36
4.3 REGIONAL SNAPSHOT OF THE HEMODYNAMIC MONITORING SYSTEMS MARKET 37
4.4 HEMODYNAMIC MONITORING SYSTEMS MARKET, BY TYPE (2014 VS. 2019) 37

5 MARKET OVERVIEW 38
5.1 INTRODUCTION 39
5.2 MARKET SEGMENTATION 39
5.3 MARKET DYNAMICS 40
5.3.1 DRIVERS 40
5.3.1.1 Technological advancements in hemodynamic monitoring systems 40
5.3.1.1.1 Noninvasive hemodynamic monitoring systems 41
5.3.1.1.2 Micro-Electro-Mechanical Systems (MEMS) technology 41
5.3.1.2 Growth in the number of people suffering from hypertension 41
5.3.1.3 Growing diabetic population 41
5.3.1.4 Rapid growth in aging population 43
5.3.2 RESTRAINTS 44
5.3.2.1 Risks associated with invasive hemodynamic monitoring 44
5.3.3 OPPORTUNITIES 45
5.3.3.1 India and China to provide significant growth opportunities for the hemodynamic monitoring systems market 45

6 INDUSTRY TRENDS 46
6.1 PORTER’S FIVE FORCES ANALYSIS 46
6.1.1 SUPPLIER’S BARGAINING POWER 46
6.1.1.1 Presence of a large number of suppliers 47
6.1.1.2 Low dependency on single supplier 47
6.1.1.3 Dependency on type of technology 47
6.1.2 BUYER’S BARGAINING POWER 47
6.1.2.1 Large supplier pool 47
6.1.3 THREAT OF NEW ENTRANTS 47
6.1.3.1 Capital-intensive market 47
6.1.3.2 Stronghold of existing players 47
6.1.3.3 Reimbursement coverage 47
6.1.4 THREAT OF SUBSTITUTES 48
6.1.4.1 Lack of alternatives 48
6.1.5 INTENSITY OF COMPETITIVE RIVALRY 48
6.1.5.1 Presence of a large number of small firms 48
6.2 SUPPLY CHAIN ANALYSIS 48
6.2.1 PROMINENT COMPANIES 49
6.2.2 SMALL AND MEDIUM ENTERPRISES 49
6.2.3 END USERS (PATIENTS/HOSPITALS/LABS/CLINICS) 49
6.2.4 KEY INFLUENCERS 50

7 HEMODYNAMIC MONITORING SYSTEMS MARKET, BY PRODUCT 51
7.1 INTRODUCTION 52
7.2 SYSTEMS (MONITORS) 53
7.2.1 DISPLAY SYSTEMS 53
7.2.2 UNIFIED HEMODYNAMIC MONITORING SYSTEMS 53
7.3 DISPOSABLES 56
7.3.1 BALLOON CATHETERS 56
7.3.2 MEASUREMENT PROBES 56
7.3.3 SENSORS 57
7.3.4 GUIDEWIRES 57

8 HEMODYNAMIC MONITORING SYSTEMS MARKET, BY TYPE 60
8.1 INTRODUCTION 61
8.2 INVASIVE HEMODYNAMIC MONITORING SYSTEMS 63
8.2.1 APPLICATIONS OF INVASIVE HEMODYNAMIC MONITORING SYSTEMS 63
8.2.2 RISKS ASSOCIATED WITH INVASIVE HEMODYNAMIC MONITORING 63
8.2.3 PRODUCTS 64
8.3 MINIMALLY INVASIVE HEMODYNAMIC MONITORING SYSTEMS 66
8.3.1 APPLICATIONS 67
8.3.2 PRODUCTS 67
8.4 NONINVASIVE HEMODYNAMIC MONITORING SYSTEMS 70
8.4.1 PRODUCTS 70

9 HEMODYNAMIC MONITORING SYSTEMS MARKET, BY END USER 74
9.1 INTRODUCTION 75
9.2 HOSPITALS 77
9.3 CATHETERIZATION LABORATORIES (CATH LABS) 79
9.4 HOME AND AMBULATORY SITES 81

10 HEMODYNAMIC MONITORING SYSTEMS MARKET, BY REGION 84
10.1 INTRODUCTION 85
10.2 NORTH AMERICA 86
10.2.1 U.S. 89
10.2.1.1 Growing diabetes prevalence to boost the market for hemodynamic monitoring systems 89
10.2.1.2 Reimbursement offerings by companies to drive the market 89
10.2.2 CANADA 90
10.2.2.1 High diabetes prevalence to boost the market for hemodynamic monitoring systems 90
10.3 EUROPE 92
10.3.1 GERMANY 94
10.3.1.1 High Diabetes Prevalence to Accelerate the Market Growth in Germany 94
10.3.1.2 S3 guidelines for intensive care in cardiac surgeries 94
10.3.2 U.K. 96
10.3.2.1 Rising prevalence of diabetes and cardiovascular diseases in the U.K. 96
10.3.3 REST OF EUROPE (ROE) 97
10.3.3.1 SFAR guidelines in France have made ODM (Oesophageal Doppler Monitors) a standard of care in the country 97
10.3.3.2 High diabetes prevalence in Russia, Turkey, Poland, Romania, and Ukraine to propel the market for hemodynamic monitoring systems in these countries 98
10.4 ASIA 99
10.4.1 JAPAN 101
10.4.1.1 Reimbursement offerings by LiDCO Group plc in Japan to propel the market growth 101
10.4.2 CHINA 103
10.4.2.1 High diabetes incidence and rapidly aging population to drive the market in China 103
10.4.3 INDIA 104
10.4.3.1 Increased demand for critical care units and high diabetes incidence to drive the market in India 104
10.4.4 REST OF ASIA 106
10.4.4.1 Adoption of hemodynamic monitoring systems in Vietnam, Singapore, & Malaysia to increase owing to high diabetes prevalence 106
10.4.4.2 Tensys Medical’s strong marketing strategy to bolster the market for noninvasive hemodynamic monitoring in China and Taiwan 106
10.5 REST OF THE WORLD (ROW) 108
10.5.1 LATIN AMERICA 110
10.5.1.1 High diabetes prevalence in Brazil 110
10.5.2 MIDDLE EAST AND AFRICA 111
10.5.2.1 Rise in adoption of hemodynamic monitoring systems in the Middle East & Africa due to high diabetes prevalence 111
10.5.3 PACIFIC COUNTRIES 112
10.5.3.1 High diabetes prevalence and rising incidence of CVDs to drive the growth of hemodynamic monitoring systems in Pacific Countries 112

11 COMPETITIVE LANDSCAPE 115
11.1 OVERVIEW 115
11.2 MARKET SHARE ANALYSIS 116
11.2.1 EDWARDS LIFESCIENCES CORPORATION 116
11.2.2 PULSION MEDICAL SYSTEMS SE 118
11.2.3 LIDCO GROUP PLC 118
11.3 COMPETITIVE SITUATION AND TRENDS 119
11.3.1 AGREEMENTS, PARTNERSHIPS, JOINT VENTURES, AND COLLABORATIONS 120
11.3.2 EXPANSIONS 121
11.3.3 MERGERS AND ACQUISITIONS 122
11.3.4 NEW PRODUCT LAUNCHES 123
11.3.5 OTHERS 124

12 COMPANY PROFILES 125
12.1 INTRODUCTION 125
12.2 CHEETAH MEDICAL, INC. 126
12.3 DELTEX MEDICAL GROUP PLC 128
12.4 EDWARDS LIFESCIENCES CORPORATION 130
12.5 HEMO SAPIENS, INC. 133
12.6 ICU MEDICAL, INC. 134
12.7 LIDCO GROUP PLC 136
12.8 OSYPKA MEDICAL GMBH 139
12.9 PULSION MEDICAL SYSTEMS SE 141
12.10 SCHWARZER CARDIOTEK GMBH 143
12.11 TENSYS MEDICAL, INC. 145
*Details On Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured In Case Of Unlisted Companies.

13 APPENDIX 147
13.1 DISCUSSION GUIDE 147
13.2 COMPANY DEVELOPMENTS (2012–2014) 150
13.2.1 LIDCO GROUP PLC 150
13.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 151
13.4 AVAILABLE CUSTOMIZATIONS 151
13.5 RELATED REPORTS 152